SCHEMBL231849

SCHEMBL231849

COC(=O)c1cc(C(=O)c2ccc(N(C)c3ccc(Cl)cc3)cc2)cc(N(C(=O)C2CCC2)c2ccccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
LTC4S Q16873 7/20 0.40
RHOA P61586 2/20 0.39
NR1H4 Q96RI1 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
PTGIR P43119 1/20 0.36
CXCR3 P49682 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
HSD17B10 Q99714 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
NOD2 Q9HC29 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231747 0.90 LTC4S (0.44) LMNAL3MBTL1LTC4SRHOACXCR3
SCHEMBL232232 0.85 LMNA (0.50) LMNAL3MBTL1LTC4SMEN1KMT2A
SCHEMBL230183 0.82 LTC4S (0.38) LMNAL3MBTL1LTC4S
SCHEMBL232400 0.80 HPGD (0.46) LMNAL3MBTL1LTC4SMEN1KMT2A
SCHEMBL231253 0.77 LMNA (0.46) LMNAL3MBTL1LTC4SMEN1KMT2A
SCHEMBL232108 0.77 MAPT (0.44) LMNAL3MBTL1LTC4SMEN1KMT2A
SCHEMBL231986 0.76 RAB9A (0.47) LMNAL3MBTL1MEN1KMT2AHSD17B10
SCHEMBL230032 0.75 MAPT (0.44) LMNAL3MBTL1LTC4SMEN1KMT2A
SCHEMBL229900 0.75 TUBB4A (0.45) LMNAL3MBTL1LTC4SMEN1KMT2A
SCHEMBL2743206 0.74 LTC4S (0.49) LMNAL3MBTL1LTC4SPTGIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R LMNA 1141/4885L3MBTL1 324/4885LTC4S 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.